Great opportunity for public to provide comments and Insight to FDA about compounding

• 
  

• FDA Opens General Docket For Human Drug Compounding

  FDA opened a public docket so stakeholders can share information, research and ideas on matters relating to human drug compounding that does not deal with documents or issues addressed in other dockets, the agency announced Monday (March 9) in the Federal Register.

  “This information will give the Agency insight into stakeholders' experiences and views regarding human drug compounding as the Agency works to implement sections 503A and 503B of the [Food Drug and Cosmetic Act],” says FDA.

  147 words